Search Results
Your search for The matches 34679 pages
Showing 11201 - 11250Surgical Oncologist Diane M. Simeone, MD, Strives to Improve Outcomes for Patients With Pancreatic Cancer
Despite decades of research and clinical advances, the diagnosis and treatment of pancreatic cancer remain formidable challenges. Recently, enormous efforts have been made to develop new methods for the early diagnosis and treatment of pancreatic cancer, such as those led by Diane M. Simeone, MD, a ...
Addition of Veliparib to Carboplatin/Paclitaxel in BRCA-Mutated Advanced Breast Cancer
As reported in The Lancet Oncology by Véronique Diéras, MD, of the Institut Curie, Paris, and Centre Eugène Marquis, Rennes, and colleagues, the phase III BROCADE3 trial has shown a significant improvement in progression-free survival with the addition of the poly (ADP-ribose) polymerase (PARP)...
Trends to Watch in Early-Onset Cancer Among Young Adults
Although cancer incidence and mortality rates for all cancers combined are considerably lower in younger adults than older adults, a disturbing pattern is beginning to emerge in the development of early-onset cancers, typically diagnosed in older patients, occurring in younger adults. The rising...
Pralsetinib for NSCLC With RET Gene Fusions
On September 4, 2020, pralsetinib (Gavreto) was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for treatment of adults with metastatic RET fusion–positive non–small cell lung cancer (NSCLC) as detected by an FDA-approved test.1,2 The FDA simultaneously approved the...
A Leader in Drug Development, Patricia Keegan, MD, Reflects on Making a Difference in Cancer Care
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Patricia Keegan, MD, who served at the U.S. Food and Drug Administration (FDA) for 30 years, most recently as Acting Associate Director of Medical Policy at the Oncology Center for Excellence (OCE)....
Dana-Farber Cancer Institute to Establish Benderson Family Program for Triple-Negative Breast Cancer
Dana-Farber Cancer Institute has received a $5 million gift from the Benderson Family of Sarasota, Florida, that will accelerate research in triple-negative breast cancer (TNBC) and strengthen Dana-Farber’s capabilities for treating this disease. The gift establishes the Benderson Family Program...
How Anxiety, Depression, and Low Social Support Impact the Intensity of Cancer Pain
Pain is one of the most common byproducts of cancer and its treatment. Tumors, surgery, intravenous chemotherapy, radiation therapy, targeted therapy, supportive care therapies (such as bisphosphonates), and diagnostic procedures can all cause pain in patients and may contribute to symptoms of...
Impact of Cytotoxic Chemotherapy Within 5 Weeks of COVID-19 Diagnosis in Patients With Cancer
In a single-institution study reported in the Journal of Clinical Oncology, Justin Jee, MD, PhD, of the Department of Medicine, Memorial Sloan Kettering Cancer Center (MSK), New York, and colleagues found that receipt of cytotoxic chemotherapy within 35 days of COVID-19 diagnosis in patients with...
Rucaparib Produces Durable Responses in Previously Treated Metastatic Castration-Resistant Prostate Cancer
As reported in the Journal of Clinical Oncology by Wassim Abida, MD, PhD, of Memorial Sloan Kettering Cancer Center, and colleagues, the phase II TRITON2 trial has shown that the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib produced durable responses in patients with previously treated...
Eliminating Routine Opioids While Maintaining Pain Control for Women Undergoing Lumpectomy or Excisional Biopsy
Changing from routinely prescribing opioids for patients who were having a lumpectomy or excisional biopsy to instead routinely prescribing nonsteroidal anti-inflammatory drugs [NSAIDs] resulted in a sharply decreased opioid prescription rate with “no difference in the proportion of patients...
Addition of Nelarabine to Standard Therapy Improves Disease-Free Survival in Newly Diagnosed T-Cell ALL
As reported in the Journal of Clinical Oncology by Kimberly P. Dunsmore, MD, of the Virginia Tech Carilion School of Medicine and Carilion Clinic, Roanoke, and colleagues, the phase III Children’s Oncology Group AALL0434 trial has shown that the addition of nelarabine to standard therapy improved...
Debbie’s Dream Foundation Launches New COVID-19 Resources and Support Program
Debbie’s Dream Foundation: Curing Stomach Cancer (DDF) recently announced its new COVID-19 Resources and Support Program. The program’s primary goal is to support, educate, and protect the already vulnerable stomach cancer community during the pandemic. The new initiative will help patients with...
Expert Point of View: Elizabeth Smyth, MD
The overall survival benefit for PD-L1 CPS ≥ 5 tumors in CheckMate 649 is a game-changer. An oxaliplatin doublet plus chemotherapy should become a standard of care for these patients,” according to Elizabeth Smyth, MD, an oncology consultant at Cambridge University Hospital NHS Foundation Trust in...
Nivolumab Plus Chemotherapy: New Standard of Care in Advanced Gastric Cancer?
As first-line treatment for advanced gastric cancer, nivolumab plus chemotherapy leads to significantly improved progression-free and overall survival over chemotherapy alone, investigators reported during a Presidential Symposium of the European Society for Medical Oncology (ESMO) Virtual Congress ...
Immunologist Thirumala-Devi Kanneganti, PhD, Receives NCI Outstanding Investigator Award
Thirumala-Devi Kanneganti, PhD, Vice Chair of the St. Jude Children’s Research Hospital Department of Immunology, has received a National Cancer Institute (NCI) Outstanding Investigator Award to build on her discoveries related to the innate immune system, inflammation, and cell death in health and ...
Carfilzomib and Daratumumab With Dexamethasone for Relapsed or Refractory Multiple Myeloma
On August 20, 2020, carfilzomib and daratumumab were approved for use in combination with dexamethasone for treatment of adults with relapsed or refractory multiple myeloma who have received one to three lines of therapy.1-3 Supporting Efficacy Data Approval was based on findings in two clinical...
Total Neoadjuvant Therapy for Pancreatic Adenocarcinoma
Patients with pancreatic adenocarcinoma who underwent total neoadjuvant therapy, consisting of chemotherapy followed by chemoradiation prior to surgery, had improved overall survival compared with those who had single-agent neoadjuvant therapy or surgery first, according to a large cohort study...
Expert Point of View: Johan Vansteenkiste, MD
Formal study discussant Johan Vansteenkiste, MD, of the University Hospitals KU Leuven, Belgium, commented on the ADAURA trial findings: “This is an impressive effect on disease-free survival [with osimertinib] and a very early snapshot of overall survival.” Dr. Vansteenkiste continued: “In the CNS ...
Impact of Adjuvant Osimertinib on CNS Recurrence of NSCLC: ADAURA Trial
Osimertinib significantly prolonged disease-free survival compared with placebo in patients with completely resected stage II to IIIA non–small cell lung cancer (NSCLC), according to the results of the large randomized phase III ADAURA trial presented at the European Society for Medical Oncology...
Expert Point of View: Rafal Dziadziuszko, MD
Commenting on the Lung ART study, Rafal Dziadziuszko, MD, a radiation oncologist from the Medical University of Gdansk, Poland, said: “Congratulations on this study to resolve the longest ongoing debate in thoracic oncology. For more than 20 years, we have been discussing whether to irradiate...
Study Questions Role of Routine Postoperative Radiotherapy in NSCLC With Mediastinal Nodes
The Lung ART trial was designed to demonstrate whether there is any benefit to the routine use of modern mediastinal postoperative radiotherapy in patients with non–small cell lung cancer (NSCLC) stage IIIA N2 (ie, patients with mediastinal nodal involvement) following complete resection and neo...
Expert Point of View: Camillo Porta, MD
Acknowledging there are now expanded therapeutic choices in the first-line setting for advanced renal cell carcinoma, formal study discussant Camillo Porta, MD, of the University of Bari Aldo Moro, Italy, said that studies of the immunotherapy combinations could not be compared directly. “We should ...
First-Line Nivolumab Plus Cabozantinib Improves Outcomes vs Sunitinib in Advanced Renal Cell Carcinoma
The combination of nivolumab plus cabozantinib was found to be superior to the former standard, sunitinib, in the first-line treatment of advanced or metastatic renal cell carcinoma, according to the results of the phase III CheckMate 9ER trial reported at the European Society for Medical Oncology...
A Primary Care Physician Explores Barriers to Cancer Prevention and Clinical Trial Accrual
To accelerate progress in the survival rates of people with cancer in the United States and to reduce cancer disparities across the entire spectrum of cancer from diagnosis to survivorship, there needs to be increased access to cancer screening and prevention programs. To shed light on this...
Mobilizing for Greater Equity in Health Care Despite the Challenges of COVID-19
The lockdown phase of the coronavirus (COVID-19) pandemic and continued measures, such as social distancing, while necessary, are disrupting cancer care in ways that will have consequences for months, if not years, to come. Studies are showing that delayed or suspended cancer treatments,...
Expert Point of View: George W. Sledge, Jr, MD
The results of monarchE were discussed by George W. Sledge, Jr, MD, Professor of Medicine and Chief of Oncology at Stanford University Medical Center, who offered some possibilities as to why its results were positive and those for palbociclib, in the phase III PALLAS trial, were “resoundingly...
Addition of Abemaciclib to Endocrine Therapy Reduces Recurrence in Early Breast Cancer
For the first time, an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6) has reduced the risk of invasive disease recurrence in patients with early breast cancer when combined with standard endocrine therapy, investigators reported at the European Society for Medical Oncology (ESMO) Virtual...
$111 Million NIH Grant Awarded to Prevent and Treat HIV-Associated Cancers
The widespread use of antiretroviral therapy to suppress the human immunodeficiency virus (HIV) has helped tens of millions of people with HIV live healthier, longer lives—but an unfortunate consequence of people living longer with HIV is an increased risk of cancer. For 25 years, the AIDS...
LUNGevity Foundation Recognizes Recipients of 2020 Career Development Awards
LUNGevity Foundation, a nonprofit organization, recently announced three recipients of its 2020 Career Development Awards for lung cancer research. These awards were presented to Kathyrn Arbour, MD, Assistant Attending at Memorial Sloan Kettering Cancer Center; Carl Gay, MD, PhD, of The University...
My Inherited Condition Has Led to a Life and Career I Love
My father died of thymic cancer when I was 14, and that’s when I decided to become an oncologist. Ironically, the first patient I diagnosed with cancer was me. In 2009, during my first week of training in hematology/oncology at the Mayo Clinic, I began having severe abdominal pain, which had...
City of Hope Hires Stephen Gruber, MD, PhD, MPH, to Head Its Center for Precision Medicine
Cancer geneticist Stephen Gruber, MD, PhD, MPH, has joined City of Hope as Director of its newly founded Center for Precision Medicine. He will lead a team of more than 14 researchers who will work across the institution to pioneer personalized cancer prevention and treatment plans. As a medical...
2020 Class of Giants of Cancer Care Announced
The Eighth Annual Giants of Cancer Care class of inductees was recently announced by OncLive, a multimedia resource focused on providing oncology professionals with relevant information on patient care. The virtual awards ceremony will be held on November 5 at 7.30 PM EST and will be available...
Study Finds Racial Disparities in Management of Colorectal Cancer Spreading to the Liver
Colorectal cancer is more prevalent among Black people, a group with the highest rates of death for an illness that is curable if caught early. “The unfortunate reality is that minorities, especially Black people, have a much lower chance of getting life-saving cancer treatment. Health care works...
Neck Tumor
The text and photographs here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Anesthesia Era 1845–1875 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...
University of Rochester School of Medicine and Dentistry Names Ruth O’Regan, MD, Chair, Department of Medicine
Ruth O’Regan, MD, Chief of Hematology, Medical Oncology and Palliative Care at the University of Wisconsin, has been named the next Charles A. Dewey Professor and Chair of Medicine at the University of Rochester Medical Center’s (URMC) School of Medicine and Dentistry, pending approval by the...
Cedars-Sinai Announces Addition of New Researchers, Physicians to Faculty
In a news release issued earlier this month, Dan Theodorescu, MD, PhD, Director of Cedars-Sinai Cancer Center in Los Angeles, welcomed several new researchers and physicians to the faculty of the institution. “I am very grateful to the institutional leadership that our efforts to expand the breadth ...
A Young Oncologist Cares for Patients With Cancer Amid COVID-19 Pandemic
The COVID-19 pandemic changed the face of U.S. health-care services in such rapid fashion that many providers were caught off guard, learning and preparing on the fly. Patients with cancer, given their multiple physical and emotional challenges, were especially vulnerable. To get a sense of the...
Phase III NALA Trial Meets Primary Endpoint in Previously Treated HER2-Positive Breast Cancer
As reported in the Journal of Clinical Oncology by Cristina Saura, MD, of Vall d’Hebron University Hospital, Barcelona, and colleagues, the phase III NALA trial has shown significantly prolonged progression-free survival with the irreversible pan-HER tyrosine kinase inhibitor neratinib plus...
City of Hope Scientists Explore Combination Immunotherapy for Solid Tumors
City of Hope scientists have combined two immunotherapies—an oncolytic virus and chimeric antigen receptor (CAR) T-cell therapy—to target solid tumors that are otherwise difficult to treat with CAR T-cell therapy alone, according to a recent study in Science Translational Medicine.1 In preclinical...
Tucatinib Combination Extends Survival in HER2-Positive Metastatic Breast Cancer, Including Patients With Brain Metastases
For patients with progressing HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and ado-trastuzumab emtansine (T-DM1), no single regimen is an established standard of care. More than 50% of these patients will develop brain metastasis, and thus far, treatments...
Wesley Family Donates $10 Million to Seidman Cancer Center
In honor of a transformational $10 million gift from Kimberly and Joseph Wesley, University Hospitals is establishing the Wesley Center for Immunotherapy at University Hospitals (UH) Seidman Cancer Center in Cleveland. This gift will further enable physician-scientists to engage in groundbreaking...
Deirdre J. Cohen, MD, MS, Appointed Director of Mount Sinai Health System’s GI Oncology Program
Deirdre J. Cohen, MD, MS, an expert in pancreatic and other gastrointestinal cancers as well as an accomplished clinical trial leader, has joined Mount Sinai Health System as Director of the Gastrointestinal (GI) Oncology Program and Medical Director of the Cancer Clinical Trials Office at The...
Chemistry of Caring: Timeless Lessons From Oncology Fellowship
As a high school student growing up in St Petersburg, Russia, I was so obsessed with chemistry that I begged my professor for extra problems to complete after school. When I rode the bus home on cold winter evenings, I traced chemical reactions with my finger in the frost on the window. By the...
Managing Breast Cancer in a Pregnant Patient
“One of the most challenging oncologic situations is the diagnosis of breast cancer in a young pregnant patient,” Jacqueline Jeruss, MD, PhD, Associate Dean, Regulatory Affairs; Director of the Breast Care Center; and Professor of Surgery, Pathology, and Biomedical Engineering at the University of...
High-Risk, HER2-Positive Breast Cancer: Neoadjuvant and Adjuvant Treatment Options
Although most patients with breast cancer are considered to have an overall excellent prognosis, 600,000 people still die annually of the disease around the world. Even in HER2-positive breast cancer, a subtype that has seen a transformation of outcomes in the past 2 decades, there’s still room for ...
A Leading Light in Cancer Advances, Mary Lasker Used Wealth and Connections to Increase Funding for Medical Research
Born in Watertown, Wisconsin, in 1900, Mary Woodard Lasker was introduced to the ravages of cancer when she was just 3 or 4 years old and went with her mother to visit the family’s laundress, Mrs. Belter, who had just undergone surgery for breast cancer. On the way over to Mrs. Belter’s home, Ms....
HER2-Positive Metastatic Breast Cancer Highlights 2019–2020 Almanac
The past 2 years have seen a dramatic change in the standard of care for patients with HER2-positive metastatic breast cancer whose disease has progressed on trastuzumab. Promising new agents and combinations for later lines of therapy may also challenge current treatment strategies, according to...
Cancer in Older Adults: The History of Geriatric Oncology, 1980–2015
The development of geriatric oncology has been slow but progressive. Thanks to the effort of investigators throughout the world, embattled but undeterred by the objection of a cautious establishment, geriatric oncology has provided a blueprint for the treatment of cancer in the population of...
Dana-Farber Researcher Receives Victoria Mock New Investigator Award
Robert Knoerl, PhD, RN, Instructor in Medicine and Nurse-Scientist at the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at Dana-Farber Cancer Institute, has been awarded the 2020 Oncology Nursing Society’s Victoria Mock New Investigator Award. This prestigious award is ...
Astragalus
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien Hou, PharmD, DipIOM, LAc, and Jyothirmai Gubili, MS, focus on the...
